The FDA also granted the treatment priority review. If approved, the treatment will be the first such treatment for the chronic inflammatory disease.
TAK-721 is an investigational therapy budesonide oral suspension. The FDA previously granted it breakthrough therapy designation and orphan drug designation.
EoE is a chronic inflammatory disease that damages the esophagus. The disease affects 1 out of every 2,000 Americans, with increases expected. The exact cause of the disease remains unknown.
The drug is currently in the middle of the largest EoE phase 3 clinical trial program in the U.S.
More articles on surgery centers:
10 recent ASC leadership moves
Virginia ASC takes infection prevention to new level — 3 insights
Surgery Partners goes all-in on cardiology — 5 quotes on its quarterly performance
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
